A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Varian, a Siemens Healthineers Company
Eli Lilly and Company
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Actuate Therapeutics Inc.
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center
National Cancer Institute (NCI)
Brigham and Women's Hospital
Novartis
Pfizer
Tomsk National Research Medical Center of the Russian Academy of Sciences
University of California, Davis
Replimune, Inc.
City of Hope Medical Center
Carevive Systems, Inc.
University of Pennsylvania
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Seagen Inc.
AgonOx, Inc.
Eli Lilly and Company
Novartis
Inhibrx Biosciences, Inc
Incyte Corporation
Complement Theory Inc.
University Health Network, Toronto
City of Hope Medical Center
AstraZeneca
M.D. Anderson Cancer Center
Turning Point Therapeutics, Inc.
HUYABIO International, LLC.
Jonsson Comprehensive Cancer Center
Milton S. Hershey Medical Center
Compugen Ltd
M.D. Anderson Cancer Center
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
National Cancer Institute (NCI)
University of Colorado, Denver
NextCure, Inc.
Baltimore VA Medical Center
Comprehensive Support Project for Oncology Research